Skip to main content
Top
Published in: Arthritis Research & Therapy 3/2006

Open Access 01-06-2006 | Research article

Activation of transforming growth factor-β1and early atherosclerosis in systemic lupus erythematosus

Authors: Michelle Jackson, Yasmeen Ahmad, Ian N Bruce, Beatrice Coupes, Paul EC Brenchley

Published in: Arthritis Research & Therapy | Issue 3/2006

Login to get access

Abstract

The efficiency of activating latent transforming growth factor (TGF)-β1 in systemic lupus erythematosus (SLE) may control the balance between inflammation and fibrosis, modulating the disease phenotype. To test this hypothesis we studied the ability to activate TGF-β1 in SLE patients and control individuals within the context of inflammatory disease activity, cumulative organ damage and early atherosclerosis. An Activation Index (AI) for TGF-β1 was determined for 32 patients with SLE and 33 age-matched and sex-matched control individuals by quantifying the increase in active TGF-β1 under controlled standard conditions. Apoptosis in peripheral blood mononuclear cells was determined by fluorescence-activated cell sorting. Carotid artery intima-media thickness was measured using standard Doppler ultrasound. These measures were compared between patients and control individuals. In an analysis conducted in patients, we assessed the associations of these measures with SLE phenotype, including early atherosclerosis. Both intima-media thickness and TGF-β1 AI for SLE patients were within the normal range. There was a significant inverse association between TGF-β1 AI and levels of apoptosis in peripheral blood mononuclear cells after 24 hours in culture for both SLE patients and control individuals. Only in SLE patients was there a significant negative correlation between TGF-β1 AI and low-density lipoprotein cholesterol (r = -0.404; P = 0.022) and between TGF-β1 AI and carotid artery intima-media thickness (r = -0.587; P = 0.0004). A low AI was associated with irreversible damage (SLICC [Systemic Lupus International Collaborating Clinics] Damage Index ≥1) and was inversely correlated with disease duration. Intima-media thickness was significantly linked to total cholesterol (r = 0.371; P = 0.037). To conclude, in SLE low normal TGF-β1 activation was linked with increased lymphocyte apoptosis, irreversible organ damage, disease duration, calculated low-density lipoprotein levels and increased carotid IMT, and may contribute to the development of early atherosclerosis.
Appendix
Available only for authorised users
Literature
1.
go back to reference Letterio JJ, Roberts AB: Regulation of immune responses by TGF-beta. Annu Rev Immunol. 1998, 16: 137-161. 10.1146/annurev.immunol.16.1.137.CrossRefPubMed Letterio JJ, Roberts AB: Regulation of immune responses by TGF-beta. Annu Rev Immunol. 1998, 16: 137-161. 10.1146/annurev.immunol.16.1.137.CrossRefPubMed
2.
go back to reference Geiser AG, Letterio JJ, Kulkarni AB, Karlsson S, Roberts AB, Sporn MB: Transforming growth factor-beta1 (TGF-beta1) controls expression of major histocompatibility genes in the postnatal mouse – aberrant histocompatibility antigen expression in the pathogenesis of the TGF-beta1 null mouse phenotype. Proc Natl Acad Sci USA. 1993, 90: 9944-9948. 10.1073/pnas.90.21.9944.PubMedCentralCrossRefPubMed Geiser AG, Letterio JJ, Kulkarni AB, Karlsson S, Roberts AB, Sporn MB: Transforming growth factor-beta1 (TGF-beta1) controls expression of major histocompatibility genes in the postnatal mouse – aberrant histocompatibility antigen expression in the pathogenesis of the TGF-beta1 null mouse phenotype. Proc Natl Acad Sci USA. 1993, 90: 9944-9948. 10.1073/pnas.90.21.9944.PubMedCentralCrossRefPubMed
3.
go back to reference Dang H, Geiser AG, Letterio JJ, Nakabayashi T, Kong L, Fernandes G, Talal N: SLE-like autoantibodies and Sjogren's syndrome-like lymphoproliferation in TGF-beta knockout mice. J Immunol. 1995, 155: 3205-3212.PubMed Dang H, Geiser AG, Letterio JJ, Nakabayashi T, Kong L, Fernandes G, Talal N: SLE-like autoantibodies and Sjogren's syndrome-like lymphoproliferation in TGF-beta knockout mice. J Immunol. 1995, 155: 3205-3212.PubMed
4.
go back to reference Ohtsuka K, Gray JD, Stimmler MM, Toro B, Horwitz DA: Decreased production of TGF-beta by lymphocytes from patients with systemic lupus erythematosus. J Immunol. 1998, 160: 2539-2545.PubMed Ohtsuka K, Gray JD, Stimmler MM, Toro B, Horwitz DA: Decreased production of TGF-beta by lymphocytes from patients with systemic lupus erythematosus. J Immunol. 1998, 160: 2539-2545.PubMed
5.
go back to reference Ohtsuka K, Gray JD, Quismorio FP, Lee W, Horwitz DA: Cytokine-mediated down-regulation of B cell activity in SLE: effects of interleukin-2 and transforming growth factor-beta. Lupus. 1999, 8: 95-102. 10.1191/096120399678847498.CrossRefPubMed Ohtsuka K, Gray JD, Quismorio FP, Lee W, Horwitz DA: Cytokine-mediated down-regulation of B cell activity in SLE: effects of interleukin-2 and transforming growth factor-beta. Lupus. 1999, 8: 95-102. 10.1191/096120399678847498.CrossRefPubMed
6.
go back to reference Bruce IN, Gladman DD, Urowitz MB: Premature atherosclerosis in systemic lupus erythematosus. Rheum Dis Clin North Am. 2000, 26: 257-278. 10.1016/S0889-857X(05)70138-1.CrossRefPubMed Bruce IN, Gladman DD, Urowitz MB: Premature atherosclerosis in systemic lupus erythematosus. Rheum Dis Clin North Am. 2000, 26: 257-278. 10.1016/S0889-857X(05)70138-1.CrossRefPubMed
7.
go back to reference Grainger DJ: Transforming growth factor beta and atherosclerosis: so far, so good for the protective cytokine hypothesis. Arterioscler Thromb Vasc Biol. 2004, 24: 399-404. 10.1161/01.ATV.0000114567.76772.33.CrossRefPubMed Grainger DJ: Transforming growth factor beta and atherosclerosis: so far, so good for the protective cytokine hypothesis. Arterioscler Thromb Vasc Biol. 2004, 24: 399-404. 10.1161/01.ATV.0000114567.76772.33.CrossRefPubMed
8.
go back to reference Grainger DJ, Kemp PR, Liu AC, Lawn RM, Metcalfe JC: Activation of transforming growth factor-beta is inhibited in transgenic apolipoprotein(a) mice. Nature. 1994, 370: 460-462. 10.1038/370460a0.CrossRefPubMed Grainger DJ, Kemp PR, Liu AC, Lawn RM, Metcalfe JC: Activation of transforming growth factor-beta is inhibited in transgenic apolipoprotein(a) mice. Nature. 1994, 370: 460-462. 10.1038/370460a0.CrossRefPubMed
9.
go back to reference Grainger DJ, Mosedale DE, Metcalfe JC, Bottinger EP: Dietary fat and reduced levels of TGFbeta1 act synergistically to promote activation of the vascular endothelium and formation of lipid lesions. J Cell Sci. 2000, 113: 2355-2361.PubMed Grainger DJ, Mosedale DE, Metcalfe JC, Bottinger EP: Dietary fat and reduced levels of TGFbeta1 act synergistically to promote activation of the vascular endothelium and formation of lipid lesions. J Cell Sci. 2000, 113: 2355-2361.PubMed
10.
go back to reference Mallat Z, Tedgui A: The role of transforming growth factor beta in atherosclerosis: novel insights and future perspectives. Curr Opin Lipidol. 2002, 13: 523-529. 10.1097/00041433-200210000-00008.CrossRefPubMed Mallat Z, Tedgui A: The role of transforming growth factor beta in atherosclerosis: novel insights and future perspectives. Curr Opin Lipidol. 2002, 13: 523-529. 10.1097/00041433-200210000-00008.CrossRefPubMed
11.
go back to reference Hahn BH: Systemic lupus erythematosus and accelerated atherosclerosis. N Engl J Med. 2003, 349: 2379-2380. 10.1056/NEJMp038168.CrossRefPubMed Hahn BH: Systemic lupus erythematosus and accelerated atherosclerosis. N Engl J Med. 2003, 349: 2379-2380. 10.1056/NEJMp038168.CrossRefPubMed
12.
go back to reference Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH: Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992, 35: 630-640.CrossRefPubMed Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH: Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992, 35: 630-640.CrossRefPubMed
13.
go back to reference Gladman DD, Urowitz MB, Goldsmith CH, Fortin P, Ginzler E, Gordon C, Hanly JG, Isenberg DA, Kalunian K, Nived O, et al: The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum. 1997, 40: 809-813.CrossRefPubMed Gladman DD, Urowitz MB, Goldsmith CH, Fortin P, Ginzler E, Gordon C, Hanly JG, Isenberg DA, Kalunian K, Nived O, et al: The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum. 1997, 40: 809-813.CrossRefPubMed
14.
go back to reference Mackness MI, Durrington PN: Lipoprotein analysis for clinical studies. Lipoprotein Analysis: a Practical Approach. Edited by: Converse CA, Skinner ER. 1992, Oxford: IRL Press, 1-42. Mackness MI, Durrington PN: Lipoprotein analysis for clinical studies. Lipoprotein Analysis: a Practical Approach. Edited by: Converse CA, Skinner ER. 1992, Oxford: IRL Press, 1-42.
15.
go back to reference Coupes BM, Newstead CG, Short CD, Brenchley PE: Transforming growth factor beta 1 in renal allograft recipients. Transplantation. 1994, 57: 1727-1731.CrossRefPubMed Coupes BM, Newstead CG, Short CD, Brenchley PE: Transforming growth factor beta 1 in renal allograft recipients. Transplantation. 1994, 57: 1727-1731.CrossRefPubMed
16.
go back to reference Coupes BM, Williams S, Roberts IS, Short CD, Brenchley PE: Plasma transforming growth factor beta(1) and platelet activation: implications for studies in transplant recipients. Nephrol Dial Transplant. 2001, 16: 361-367. 10.1093/ndt/16.2.361.CrossRefPubMed Coupes BM, Williams S, Roberts IS, Short CD, Brenchley PE: Plasma transforming growth factor beta(1) and platelet activation: implications for studies in transplant recipients. Nephrol Dial Transplant. 2001, 16: 361-367. 10.1093/ndt/16.2.361.CrossRefPubMed
17.
go back to reference Sidhu PS, Desai SR: A simple and reproducible method for assessing intimal-medial thickness of the common carotid artery. Br J Radiol. 1997, 70: 85-89.CrossRefPubMed Sidhu PS, Desai SR: A simple and reproducible method for assessing intimal-medial thickness of the common carotid artery. Br J Radiol. 1997, 70: 85-89.CrossRefPubMed
18.
go back to reference Kropf J, Schurek JO, Wollner A, Gressner AM: Immunological measurement of transforming growth factor-beta I (TGF-beta 1) in blood; assay development and comparison. Clinical Chemistry. 1997, 43: 1965-1974.PubMed Kropf J, Schurek JO, Wollner A, Gressner AM: Immunological measurement of transforming growth factor-beta I (TGF-beta 1) in blood; assay development and comparison. Clinical Chemistry. 1997, 43: 1965-1974.PubMed
19.
go back to reference Grainger DJ, Wakefield L, Bethell HW, Farndale RW, Metcalfe JC: Release and activation of platelet latent TGF-beta in blood clots during dissolution with plasmin. Nature Medicine. 1995, 1: 932-937. 10.1038/nm0995-932.CrossRefPubMed Grainger DJ, Wakefield L, Bethell HW, Farndale RW, Metcalfe JC: Release and activation of platelet latent TGF-beta in blood clots during dissolution with plasmin. Nature Medicine. 1995, 1: 932-937. 10.1038/nm0995-932.CrossRefPubMed
20.
go back to reference Lawrence DA: Latent-TGF-beta: an overview. Mol Cell Biochem. 2001, 219: 163-170. 10.1023/A:1010819716023.CrossRefPubMed Lawrence DA: Latent-TGF-beta: an overview. Mol Cell Biochem. 2001, 219: 163-170. 10.1023/A:1010819716023.CrossRefPubMed
21.
go back to reference Emlen W, Niebur J, Kadera R: Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J Immunol. 1994, 152: 3685-3692.PubMed Emlen W, Niebur J, Kadera R: Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J Immunol. 1994, 152: 3685-3692.PubMed
22.
go back to reference Lorenz HM, Grunke M, Hieronymus T, Herrmann M, Kuhnel A, Manger B, Kalden JR: In vitro apoptosis and expression of apoptosis-related molecules in lymphocytes from patients with systemic lupus erythematosus and other autoimmune diseases. Arthritis Rheum. 1997, 40: 306-317.CrossRefPubMed Lorenz HM, Grunke M, Hieronymus T, Herrmann M, Kuhnel A, Manger B, Kalden JR: In vitro apoptosis and expression of apoptosis-related molecules in lymphocytes from patients with systemic lupus erythematosus and other autoimmune diseases. Arthritis Rheum. 1997, 40: 306-317.CrossRefPubMed
23.
go back to reference Perniok A, Wedekind F, Herrmann M, Specker C, Schneider M: High levels of circulating early apoptic peripheral blood mononuclear cells in systemic lupus erythematosus. Lupus. 1998, 7: 113-118. 10.1191/096120398678919804.CrossRefPubMed Perniok A, Wedekind F, Herrmann M, Specker C, Schneider M: High levels of circulating early apoptic peripheral blood mononuclear cells in systemic lupus erythematosus. Lupus. 1998, 7: 113-118. 10.1191/096120398678919804.CrossRefPubMed
24.
go back to reference Gergely P, Niland B, Gonchoroff N, Pullmann R, Phillips PE, Perl A: Persistent mitochondrial hyperpolarization, increased reactive oxygen intermediate production, and cytoplasmic alkalinization characterize altered IL-10 signaling in patients with systemic lupus erythematosus. J Immunol. 2002, 169: 1092-1101.PubMedCentralCrossRefPubMed Gergely P, Niland B, Gonchoroff N, Pullmann R, Phillips PE, Perl A: Persistent mitochondrial hyperpolarization, increased reactive oxygen intermediate production, and cytoplasmic alkalinization characterize altered IL-10 signaling in patients with systemic lupus erythematosus. J Immunol. 2002, 169: 1092-1101.PubMedCentralCrossRefPubMed
25.
go back to reference Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berger R, Cote R, Grover SA, Fortin PR, Clarke AE, Senecal JL: Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2001, 44: 2331-2337. 10.1002/1529-0131(200110)44:10<2331::AID-ART395>3.0.CO;2-I.CrossRefPubMed Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berger R, Cote R, Grover SA, Fortin PR, Clarke AE, Senecal JL: Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2001, 44: 2331-2337. 10.1002/1529-0131(200110)44:10<2331::AID-ART395>3.0.CO;2-I.CrossRefPubMed
26.
go back to reference Bruce IN: Cardiovascular disease in lupus patients: should all patients be treated with statins and aspirin?. Best Pract Res Clin Rheumatol. 2005, 19: 823-838. 10.1016/j.berh.2005.05.001.CrossRefPubMed Bruce IN: Cardiovascular disease in lupus patients: should all patients be treated with statins and aspirin?. Best Pract Res Clin Rheumatol. 2005, 19: 823-838. 10.1016/j.berh.2005.05.001.CrossRefPubMed
27.
go back to reference Grainger DJ, Byrne CD, Witchell CM, Metcalfe JC: Transforming growth factor beta is sequestered into an inactive pool by lipoproteins. J Lipid Res. 1997, 38: 2344-2352.PubMed Grainger DJ, Byrne CD, Witchell CM, Metcalfe JC: Transforming growth factor beta is sequestered into an inactive pool by lipoproteins. J Lipid Res. 1997, 38: 2344-2352.PubMed
28.
go back to reference Sakamoto YI, Miyazaki A, Tamagawa H, Wang GP, Horiuchi S: Specific interaction of oxidized low-density lipoprotein with thrombospondin-1 inhibits transforming growth factor-beta from its activation. Atherosclerosis. 2005, 183: 85-93. 10.1016/j.atherosclerosis.2005.02.032.CrossRefPubMed Sakamoto YI, Miyazaki A, Tamagawa H, Wang GP, Horiuchi S: Specific interaction of oxidized low-density lipoprotein with thrombospondin-1 inhibits transforming growth factor-beta from its activation. Atherosclerosis. 2005, 183: 85-93. 10.1016/j.atherosclerosis.2005.02.032.CrossRefPubMed
29.
go back to reference Nuttall SL, Heaton S, Piper MK, Martin U, Gordon C: Cardiovascular risk in systemic lupus erythematosus: evidence of increased oxidative stress and dyslipidaemia. Rheumatology (Oxford). 2003, 42: 758-762. 10.1093/rheumatology/keg212.CrossRef Nuttall SL, Heaton S, Piper MK, Martin U, Gordon C: Cardiovascular risk in systemic lupus erythematosus: evidence of increased oxidative stress and dyslipidaemia. Rheumatology (Oxford). 2003, 42: 758-762. 10.1093/rheumatology/keg212.CrossRef
30.
go back to reference Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, Crow MK, Schwartz JE, Paget SA, Devereux RB, Salmon JE: Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003, 349: 2399-2406. 10.1056/NEJMoa035471.CrossRefPubMed Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, Crow MK, Schwartz JE, Paget SA, Devereux RB, Salmon JE: Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003, 349: 2399-2406. 10.1056/NEJMoa035471.CrossRefPubMed
31.
go back to reference Lawn RM, Pearle AD, Kunz LL, Rubin EM, Reckless J, Metcalfe JC, Grainger DJ: Feedback mechanism of focal vascular lesion formation in transgenic apolipoprotein(a) mice. J Biol Chem. 1996, 271: 31367-31371. 10.1074/jbc.271.49.31367.CrossRefPubMed Lawn RM, Pearle AD, Kunz LL, Rubin EM, Reckless J, Metcalfe JC, Grainger DJ: Feedback mechanism of focal vascular lesion formation in transgenic apolipoprotein(a) mice. J Biol Chem. 1996, 271: 31367-31371. 10.1074/jbc.271.49.31367.CrossRefPubMed
Metadata
Title
Activation of transforming growth factor-β1and early atherosclerosis in systemic lupus erythematosus
Authors
Michelle Jackson
Yasmeen Ahmad
Ian N Bruce
Beatrice Coupes
Paul EC Brenchley
Publication date
01-06-2006
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 3/2006
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar1951

Other articles of this Issue 3/2006

Arthritis Research & Therapy 3/2006 Go to the issue